BR112018068116A2 - película transmucosal para administração de montelucaste - Google Patents

película transmucosal para administração de montelucaste

Info

Publication number
BR112018068116A2
BR112018068116A2 BR112018068116A BR112018068116A BR112018068116A2 BR 112018068116 A2 BR112018068116 A2 BR 112018068116A2 BR 112018068116 A BR112018068116 A BR 112018068116A BR 112018068116 A BR112018068116 A BR 112018068116A BR 112018068116 A2 BR112018068116 A2 BR 112018068116A2
Authority
BR
Brazil
Prior art keywords
active agent
pharmaceutically active
transmucosal film
administration
film
Prior art date
Application number
BR112018068116A
Other languages
English (en)
Inventor
Zerbe Horst
Conway Justin
Paiement Nadine
Obeid Rodolphe
Original Assignee
Intelgenx Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intelgenx Corp filed Critical Intelgenx Corp
Publication of BR112018068116A2 publication Critical patent/BR112018068116A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

um produto de película oral em que um agente farmaceuticamente ativo é estabilizado na sua forma parcialmente ionizada para facilitar a melhor administração por via transmucosal. a película inclui uma camada bioadesiva incluindo um agente farmaceuticamente ativo possuindo uma constante de dissociação logarítmica de ácido que é inferior a 4,5 e que é complexada com um polímero catiônico.
BR112018068116A 2016-03-11 2017-03-01 película transmucosal para administração de montelucaste BR112018068116A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/067,309 US20170258710A1 (en) 2016-03-11 2016-03-11 Montelukast transmucosal film
PCT/CA2017/050267 WO2017152272A1 (en) 2016-03-11 2017-03-01 Montelukast transmucosal film

Publications (1)

Publication Number Publication Date
BR112018068116A2 true BR112018068116A2 (pt) 2019-01-15

Family

ID=59787639

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018068116A BR112018068116A2 (pt) 2016-03-11 2017-03-01 película transmucosal para administração de montelucaste

Country Status (10)

Country Link
US (1) US20170258710A1 (pt)
EP (1) EP3426235A4 (pt)
JP (1) JP2019508437A (pt)
KR (1) KR20180119627A (pt)
CN (1) CN108778259A (pt)
AU (1) AU2017231110A1 (pt)
BR (1) BR112018068116A2 (pt)
CA (1) CA3017264A1 (pt)
MX (1) MX2018010755A (pt)
WO (1) WO2017152272A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9949934B1 (en) * 2016-10-20 2018-04-24 Intelgenx Corp. Device and method of treating conditions associated with neuroinflammation
DE102017127434A1 (de) * 2017-11-21 2019-05-23 Lts Lohmann Therapie-Systeme Ag Taschenförmige oral auflösende Filme mit hoher Wirkstoffbeladung
EP3849553A4 (en) * 2018-09-14 2022-06-22 Intelgenx Corp. TREATMENT METHOD AND DEVICE FOR IMPROVING BIOAVAILABILITY OF MONTELUKAST, A LEUKOTRIEN RECEPTOR ANTAGONIST
DE102021100779A1 (de) 2021-01-15 2022-07-21 Lts Lohmann Therapie-Systeme Ag. Mehrschichtiger oraler dünnfilm
WO2022170442A1 (en) * 2021-02-12 2022-08-18 Intelgenx Corp. Novel tryptamine oral film formulation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6904516B2 (en) * 2002-07-17 2005-06-07 Sun Microsystems, Inc. Mechanism for enabling efficient execution of an instruction
SE0300187D0 (sv) * 2003-01-24 2003-01-24 Magle Ab A smokeless tobacco substitute material
US20040156794A1 (en) * 2003-02-11 2004-08-12 Barkalow David G. Bioerodible and bioadhesive confectionery products and methods of making same
US20060246075A1 (en) * 2004-09-29 2006-11-02 Marc Mercken Anti-amyloid antibodies, compositions, methods and uses
DK2234502T4 (da) * 2007-12-21 2021-10-11 Basf Se Mikrokapsler, der omfatter et fedtopløseligt aktivt stof
US20110142889A1 (en) * 2009-12-16 2011-06-16 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
US9539334B2 (en) * 2012-05-17 2017-01-10 John Hopkins University Orally dissolving thin films containing allergens and methods of making and use
BR112015020851A2 (pt) * 2013-02-21 2017-07-18 Massachusetts Inst Technology formulação para a entrega de um agente a um local em uma cavidade mucosa e método para entregar um agente a um local em uma cavidade mucosa.
TWI596249B (zh) * 2013-04-04 2017-08-21 島精機製作所股份有限公司 鞋襪類之編織方法
US20160022595A1 (en) * 2014-07-24 2016-01-28 Rhinotopic, LLC Bioadhesive and biodegradable and formulations that provide sustained release of antimicrobials, bacteriophages and anti-inflammatory medications for inactivation of biofilms and the treatment of rhinosinusitis and other infections
US20160175245A1 (en) * 2014-12-19 2016-06-23 Mycotoxins Therapy, Llc Treatment of diseases associated with mold and mycotoxin exposure
CN104784157B (zh) * 2015-04-04 2018-06-26 齐鲁制药有限公司 一种稳定的孟鲁司特口腔薄膜剂

Also Published As

Publication number Publication date
CA3017264A1 (en) 2017-09-14
KR20180119627A (ko) 2018-11-02
CN108778259A (zh) 2018-11-09
EP3426235A4 (en) 2019-11-13
EP3426235A1 (en) 2019-01-16
JP2019508437A (ja) 2019-03-28
US20170258710A1 (en) 2017-09-14
WO2017152272A1 (en) 2017-09-14
MX2018010755A (es) 2019-02-07
AU2017231110A1 (en) 2018-10-18

Similar Documents

Publication Publication Date Title
BR112018068116A2 (pt) película transmucosal para administração de montelucaste
MX2021014509A (es) Composiciones farmaceuticas que comprenden meloxicam.
BR112018076601A2 (pt) formulação farmacêutica oral, métodos para tratar um paciente, e, uso de uma formulação
MY196173A (en) Cot Modulators And Methods Of Use Thereof
BR112018067586A2 (pt) composição administrável oralmente
BR112016029264A2 (pt) método para tratamento dos cabelos com um condicionador concentrado
BR112016029241A2 (pt) método para tratamento dos cabelos com um condicionador concentrado
CL2016002812A1 (es) Uso de ácido 3-2,3,5,6-tetrafluoro-3-trifluorometoxi-bifenil-4-ilcarbamoil-tiofeno-2-carboxílico para preparar un medicamento útil para tratar una enfermedad ocular que es uveítis, ojo seco o causada por un adenovirus composición formulación.
BR112016001678A2 (pt) Composição, método de fabricação de um comprimido, comprimido, forma de dosagem unitária, artigo de fabricação, e, uso de uma composição, de um comprimido ou de uma forma de dosagem unitária
BR112018010018A2 (pt) moduladores de ror-gama
BR112016028961A2 (pt) composições compreendendo fibras obtidas por via eletro-hidrodinâmica para administração de dosagens específicas de uma substância ativa à pele ou mucosa
EP4233889A3 (en) Activin-actrii antagonists and uses for treating myelodysplastic syndrome
CL2015002677A1 (es) Composiciones que comprenden selenio y uso de las mismas para el tratamiento y prevención de enfermedades o condiciones asociadas con la disfunción mitocondrial.
BR112016029750A2 (pt) dosagem intermitente de inibidor mdm2
CL2016001094A1 (es) Silicato de zirconio microporoso para el tratamiento de hipercalemia.
BR112015030140A2 (pt) forma de dosagem farmacêutica sólida para liberação de pelo menos um ingrediente farmacêutico ativo na cavidade oral
BR112018071082A2 (pt) benzodiazepinas nasais e inaladas oralmente
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
CL2017002214A1 (es) Formulación de combinación de tesofensina y betabloqueante
PH12016502544B1 (en) Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor
EA201991287A1 (ru) Твердые фармацевтические композиции на основе тикагрелора для перорального применения
AR096223A1 (es) Pastilla de nicotina para administración oral
BR112015023609A2 (pt) método e sistema para transferir configurações de usuário para outro dispositivo de recebimento de usuário
BR112019001178A2 (pt) biotinas e composição de biotina
CL2016001008A1 (es) Formulaciones de inyección con base en aceite de sésamo.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements